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CONSCIOUS SEDATION MEDICATION CHOICE DOES NOT AFFECT
OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT.
Diane R.M. Somlo, Syed Usman Bin Mahmood, Makoto Mori, Qingbing Zhu, John K.
Forrest, and Abeel A. Mangi. Section of Cardiac Surgery, Department of Surgery, Yale
University School of Medicine, New Haven, CT.
Conscious Sedation (CS) has become a mainstay option for anesthesia in Transcatheter
Aortic Valve Replacement (TAVR), but there has been limited investigation into the effect
of CS medication choice on patient outcomes. This study aimed to assess whether the CS
medications used in TAVR were associated with primary outcomes, including hospital
length of stay (LOS), mortality, or need for post-operative permanent pacemaker. This
retrospective, observational study included 272 patients who underwent TAVR with CS at
a tertiary teaching hospital between September 2014 and December 2017. Patient and
procedure data were collected from the STS/ACC Transcatheter Valve Therapy Registry
and chart review. Patients were grouped according to the CS medications they received
during TAVR, and three analyses were conducted from the pool of 272 patients: Propofol
versus No propofol (n=203 vs. n=64), Propofol plus midazolam versus Propofol only (n=70
vs. n=94), and Dexmedetomidine versus No dexmedetomidine (n=86 vs. n=186). Several
patient and procedure characteristics differed significantly at baseline in all three analyses.
Regression and Cox proportional hazard analyses were conducted to adjust for differences.
After adjustment, primary outcomes were not significantly different in each analysis, and
there were no differences in secondary outcomes, including in-hospital death, discharge
location, creatinine change, hemoglobin change, discharge creatinine, and incidence of
blood transfusion. Among patients with prolonged LOS, more patients in the Propofol plus
midazolam group had hypotension as a causative factor compared to the Propofol only
group (56% versus 17%, p = 0.075), even though the Propofol plus midazolam group was
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younger and less ill. Ultimately, it is unclear whether CS medication choice for TAVR
affects patient outcomes, and it is possible that medication selection can be left to provider
preference. Further analysis with larger sample sizes may be warranted, especially to study
the effect of propofol plus midazolam compared to single-sedative regimens.
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INTRODUCTION
Aortic stenosis (AS) is the most prevalent valvular disease in developed countries,1
affecting an estimated 12-13% of patients who are > 75-years old.2 In the United States
alone, an estimated 2.5 million people over the age of 75 suffer from AS.3 AS patients are
sub-classified into “at risk,” “progressive,” or “severe” based on diagnostic criteria
including patent valve area, pressure gradient, maximum aortic velocity, ventricular
dysfunction, and other measures.4,5 It is estimated that more than 25% of all current AS
cases are severe, and the number of severe AS cases increases year over year; an estimated
27,000 patients newly meet criteria for severe AS annually.2 Severe AS can either be
asymptomatic (~25%) or symptomatic (~75%),2 and symptoms include exertional dyspnea
and angina, sequelae of heart failure, and syncope or presyncope.5 Without treatment,
roughly 50% of symptomatic, severe AS patients die within 2 years, and the prognosis
continues to worsen thereafter.6-9 Since there is no medical therapy available for severe
AS, replacement of the diseased valve is crucial. Replacement can be accomplished by
either Surgical Aortic Valve Replacement (SAVR) or by Transcatheter Aortic Valve
Replacement (TAVR; Transcatheter Aortic Valve Implantation, TAVI).
While SAVR was the historical mainstay for treatment of severe, symptomatic AS,
TAVR has taken off as the less invasive and increasingly popular alternative. The pool of
TAVR-eligible patients has expanded rapidly over the last five years; in the United States,
the Food and Drug Administration (FDA) first approved TAVR for severe AS patients who
are at high surgical risk in 2015.10-13 Studies then demonstrated that TAVR is non-inferior
for intermediate-risk surgical patients as well,14-17 and the FDA subsequently expanded
eligibility to intermediate-risk patients in 2017. Finally, in 2019, the PARTNER 3
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randomized trial demonstrated noninferiority of TAVR versus SAVR even for low-risk
surgical patients with severe AS.18 About three months later, TAVR was FDA-approved
for use in low-risk surgical candidates.19-21 With this dramatic increase in TAVR eligibility,
the increasing global elderly population, and high prevalence of AS and severe AS, the
number of TAVR procedures conducted annually is likely to continue increasing.

Conscious Sedation in TAVR
Earlier in the adoption of TAVR, the procedure was exclusively completed with
patients under General Anesthesia (GA). However, as procedural knowledge has grown
over the last decade, there has been a paradigm shift in anesthetic approach: Conscious
Sedation (CS, also known as Moderate Sedation or Monitored Anesthesia Care A) has
emerged as the viable alternative to GA. GA and CS represent different depths of sedation
along the continuum of sedation.22 GA is the deepest sedation possible, where patients are
totally unresponsive to painful stimuli and require ventilation support. Conversely, CS
consists of local anesthesia and parenteral medications that induce a state of depressed
consciousness with anxiolysis and pain management. Unlike GA, CS does not require
airway intervention, and patients are able to respond purposefully to tactile and verbal
stimulation. CS generally results in less physiologic disturbance than GA, which typically
leads to faster recovery times and decreased hospital length of stay.23
Indeed, the proportion of TAVR procedures completed under CS has been
increasing. From 2013 to 2019, the percentage of transfemoral-access TAVR procedures
performed under CS rather than GA went from 33% to 64%.24 The increase in use of CS
Per the American Society of Anesthesiologists, CS is termed “Monitored Anesthesia Care” (MAC) when
administered by an anesthesiologist.

A
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was likely bolstered by multiple observational and meta-analysis studies that demonstrated
CS in TAVR results in equivalent procedure efficacy, shorter hospital stays, decreased ICU
time, and decreased total cost of care compared to GA.25-31 There has only been one
prospective study to date that has compared TAVR outcomes after randomizing patients to
GA or CS (SOLVE-TAVI), and this randomized study also found that CS resulted in
equivalent outcomes, including mortality, stroke, myocardial infarction, paravalvular leak,
and hospital and intensive care unit length of stay.32 Additionally, the authors found that
CS resulted in decreased use of inotropic agents compared to GA. Overall, anesthesia
during TAVR has trended towards a minimalist approach with lighter sedation, and it is
likely that CS will be an increasingly popular choice for anesthesia in TAVR.

Which Conscious Sedation medication regimen is optimal for TAVR?
The three most common sedatives for CS are propofol, midazolam, and
dexmedetomidine, which are usually combined with opioids such as fentanyl and
remifentanil for analgesia.33 Each medication has benefits of use as well as potential
adverse respiratory and hemodynamic effects:
•

Propofol is a sedative-hypnotic that provides limited analgesia,34 and it is the preferred
agent for sedation in interventional procedures largely because of its rapid onset and
short half-life, which allows it to be easily titrated and stopped for smooth recovery.35
However, propofol also causes dose-dependent respiratory depression and
cardiovascular depression that requires close monitoring,22 and propofol is more likely
to cause respiratory depression when co-administered with other sedatives and
opioids.33
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•

Midazolam is a benzodiazepine with both anxiolytic and anterograde amnesia effects.34
Like propofol, midazolam also does not offer analgesia and is usually paired with an
opioid. Midazolam is also a dose-dependent respiratory depressant, and it has
cardiovascular depressant effects, although these are usually minimal. Both the
respiratory and cardiac depression effects increase when midazolam is co-administered
with opioids or other sedatives.33 Midazolam and other benzodiazepines can be
reversed using flumazenil,36 but propofol does not have a reversal agent.

•

Dexmedetomidine is an alpha-2 adrenergic receptor agonist which, unlike propofol or
midazolam, offers analgesia in addition to anxiolysis and sedation.34 Dexmedetomidine
causes minimal respiratory depression, and unlike propofol and midazolam, it does not
synergize with other sedatives and opioids. However, it can induce both severe
bradycardia and transient hypertension as a result of its sympatholytic effects.33 There
are no reversal agents currently available for human use.
Even though CS is widely used for TAVR, it remains unclear whether a certain CS

medication regimen is more or less suited for TAVR patients. CS medications may not
usually be expected to influence patients’ clinical course beyond the procedure and
immediately post-procedure, but there are several reasons why sedative choice may have a
greater impact on clinical trajectory for TAVR patients. First, TAVR patients are overall
elderly and therefore more sensitive to sedatives. Among low-surgical risk TAVR patients,
the average age was 73,18 and the average age for intermediate-risk patients was 82.15
Geriatric patients are more sensitive to CS medication’s intended effects and adverse side
effects,33 and they are more susceptible to over-sedation.34 Consequently, it is recognized
that elderly patients need lower doses of sedatives and closer monitoring of hemodynamic
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response, and it may be more difficult to avoid sedative-associated complications in these
patients.
Second, the conditions that render patients eligible for TAVR likely increases their
sensitivity to adverse cardiovascular and respiratory effects of sedatives and makes it more
difficult to avoid these complications. Patients must have severe aortic valve disease and a
degree of symptomatic heart failure or measurable left ventricular dysfunction to be
eligible for TAVR,4 and these conditions result in a more friable hemodynamic system that
is likely more vulnerable to CS medication-induced hemodynamic perturbations. Indeed,
propofol, dexmedetomidine, and midazolam all decrease systemic vascular resistance, and
this creates particular risk of hypotension in patients with AS; the stenotic valve is a fixed
obstruction that causes decreased cardiac output, and decreased output drives myocardial
hypoperfusion and decreased left ventricular contractility.37 Furthermore, both propofol
and dexmedetomidine are identified as agents that can exacerbate myocardial dysfunction
and precipitate or worsen heart failure symptoms.38 While completion of TAVR would
address the valvular dysfunction and have an immediate effect on the patient’s
cardiovascular function, complications could still arise prior to valve replacement or occur
despite the replacement due to advanced age or frailty.
Overall, increased risk of sedation-associated complications for these patients
means there is increased risk that sedation choice could affect clinical course and longerterm outcomes for TAVR patients. If a patient experiences over-sedation intra-operatively,
they may need intubation to address respiratory depression or pressor support and intensive
care unit monitoring for persistent hemodynamic instability. Both outcomes after TAVR
could cause longer hospital length of stay, and prolonged hospital stay (defined as hospital
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stay greater than 72 hours) for TAVR patients is an independent predictor of 1-year allcause mortality.39 Ultimately, there is need to ascertain whether a given CS medication
combination is associated with better or worse outcomes following TAVR, because this
population has factors that increase risk of complications from sedation. If CS medications
do affect outcomes even marginally, medication adjustments could lead to improvement of
outcomes on an aggregate level due to the large number of TAVR operations conducted
with CS annually.
To date, there are four studies that explore the effect of specific CS medications on
patient outcomes after TAVR, and all four studies focus primarily on propofol versus
dexmedetomidine. First, in 2016, Khalil et al. conducted a pilot study that randomized 50
patients to receive propofol (n=25) or dexmedetomidine (n=25) as CS agents for TAVR.40
Authors found that both propofol and dexmedetomidine provided adequate sedation but
that the dexmedetomidine patients had more intra-operative hemodynamic instability:
patients treated with dexmedetomidine had significantly lower intra-operative heart rate
and mean arterial blood pressure and required more phenylephrine boluses. However,
authors found no differences between the group’s post-operative complications, including
hospital length of stay, ICU length of stay, mortality, renal failure, stroke, pulmonary
edema, peripheral ischemia, local infection, ventricular arrhythmias, and myocardial
ischemia.
Second, Mayr et al. compared propofol-opioid (n=150) versus dexmedetomidine
only (n=157) in a retrospective analysis of TAVR CS regimens in 2017.41 However, this
study focused exclusively on outcomes relating to intra-operative hemodynamics and periprocedural gas exchange, so the authors did not consider or compare post-operative
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outcomes and complications. Mayr et al. found that the dexmedetomidine patients had
significantly lower arterial partial pressure of carbon dioxide, lower frequency of
hypercapnia, and lower need for norepinephrine than the propofol group. It was noted that
conversion to GA occurred more frequently in the propofol group compared to the
dexmedetomidine group, but the difference was not statistically significant.
Third, Chen et al. conducted a single institution, retrospective study in 2017 to
compare propofol only (n=39) versus dexmedetomidine plus propofol (n=34).42 The
authors considered both post-operative outcomes and the effect of patient age on average
dose. They found no significant difference between the groups, including in incidence of
conversion to GA, total procedure time, incidence of post-operative delirium, hospital
length of stay, and intensive care unit length of stay. Additionally, they found no
association between patient age group and the doses of medications used.
Lastly, Kronfli et al. conducted a single institution, prospective observational study
in 2020 to investigate outcomes and costs after TAVR with propofol (n=58) versus
dexmedetomidine (n=103).43 This was the only study to compare costs for these agents,
and dexmedetomidine is typically a more costly agent than propofol. As was the case for
the prior studies, the authors also found no significant difference in post-operative
outcomes including in-hospital mortality, complication rate, need for pressors, and total
cost of hospitalization. This was the largest study to date that considered outcomes (i.e.,
excluding Mayr et al.), but even this study cited small sample size as a key limitation.
While these four studies have helped get closer to identifying whether a given CS
regimen is better for TAVR, the question remains open in several respects. First, these
studies focused only on propofol versus either dexmedetomidine only or propofol plus
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dexmedetomidine. However, there are other CS medication combinations that are currently
in use in TAVR that are yet to be investigated for this procedure. For instance, no study
has considered the effect of combination propofol plus midazolam versus propofol alone
or midazolam alone in TAVR. For comparison, the combination of propofol plus
midazolam has been studied for other procedures, including colonoscopy,44-46 endoscopic
procedures,47-49 and pediatric sedation for MRI.50 These studies found some differences
between the comparators, with most finding that propofol plus midazolam resulted in
deeper sedation and a longer recovery period. This could have implications for TAVR
patient recovery and should be investigated further.
Second, while these studies found no significant difference in post-operative
outcomes thus far, it is still possible that a difference exists but has not been detected. Of
the studies that considered post-operative outcomes (Khalil et al., Chen et al., and Kronfli
et al.), all three cited small sample size as a key limitation for the analyses. All three studies
also specifically noted that complications of interest occurred at a very low rate and led to
analyses that were underpowered. As a result, there is need to investigate CS medications
using larger sample sizes to identify any differences that may previously have been
obscured by small samples.
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STATEMENT OF PURPOSE
We set out to investigate whether a given CS regimen of interest is associated with
better or worse post-TAVR outcomes, with primary focus on total hospital length of stay
(LOS), mortality, and need for post-operative permanent pacemaker. Incidence of postoperative permanent pacemaker (PPM) is also a key outcome of interest, because while
other post-TAVR complications have decreased with time, incidence of post-operative
PPM has paradoxically increased51 and could be affected by CS choice, especially
propofol52 or dexmedetomidine.53
Medication Groups and Hypotheses
First, we set out to test whether CS with either propofol or propofol plus
midazolam could lead to worse outcomes after TAVR. Both propofol and
benzodiazepines cause respiratory depression, especially if they are co-administered,33,54
and respiratory depression is the most common complication of CS.33 Indeed, in a 2006
analysis of claims data, over half of the patients who experienced respiratory depression
and associated complications after CS had received propofol with or without a
benzodiazepine.55 Furthermore, geriatric patients are more susceptible to the adverse
effects of propofol and midazolam.33 As a result, these CS medications may lead to
increased risk of over sedation, which could potentially lengthen hospital stay and lead to
increased related post-procedural complications such as conversion to GA or in-hospital
death.
There is also evidence that propofol may provide less adequate post-operative
pain amelioration and may lead to increased need for post-operative pain management
One study comparing propofol to dexmedetomidine for CS in minor hysteroscopic
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surgery found that propofol resulted in worse intraoperative analgesia and higher pain
scores post-operatively.56 Another randomized trial studying the effect of propofol versus
dexmedetomidine following total knee arthroplasty with spinal anesthesia and CS found
that propofol patients required increased post-operative opioids.57 Post-operative pain and
increased opioids both increase risk of delirium,58 which is of concern for this majority
geriatric patient population and could prolong hospital stay. Overall, investigation of the
effect of propofol and propofol plus midazolam on TAVR outcomes is warranted and
will be explored via the following analyses:
•

Hypothesis A: Use of propofol for CS in TAVR, regardless of other medications
used, is associated with worse outcomes (longer LOS, increased hazard of mortality,
or increased need for post-operative PPM). Analysis A will compare outcomes after
CS with Propofol versus CS with No propofol.

•

Hypothesis B: CS in TAVR with propofol plus midazolam will be associated with
worse outcomes than CS with propofol only. Analysis B will be a comparison of
outcomes after Propofol plus midazolam versus Propofol only.

Second, we set out to investigate whether dexmedetomidine use is associated with
better outcomes after TAVR. While both Khalil et al. and Mayr et al. found that
dexmedetomidine resulted in lower intra-operative blood pressures, neither study
demonstrated worse dexmedetomidine outcomes. In fact, there are several reasons why
dexmedetomidine may be potentially beneficial for post-operative outcomes. First, a 2019
meta-analysis that found dexmedetomidine may reduce incidence of delirium after cardiac
surgery,59 and dexmedetomidine has been associated with reduced post-operative pain
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compared to propofol56,60 and overall reduced risk of acute kidney injury.61,62 Use of
dexmedetomidine is also associated with reduced risk of intra-operative respiratory
depression compared to CS with benzodiazepines or propofol with opioids.63 Indeed, in a
study of patients undergoing endoscopic retrograde cholangiopancreatography (ERCP),
patients treated with dexmedetomidine plus ketamine rather than propofol plus opioids
experienced significantly fewer adverse sedation-related events.64 Additionally, there is
some evidence that dexmedetomidine could reduce risk of arrythmias, but this evidence is
mixed.53,65,66 Overall, dexmedetomidine could potentially benefit the TAVR patient
population due to its effects on these common post-procedural complications and will be
investigated by the following analysis:
•

Hypothesis C: Use of dexmedetomidine in CS for TAVR, regardless of other
medications, will be associated with improved outcomes. Analysis C will compare
outcomes after CS with Dexmedetomidine versus CS with No Dexmedetomidine.
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METHODS
Author D. Somlo wrote, submitted, achieved approval, and re-submitted the protocol for
re-approval as necessary. This study received approval from the Institutional Review Board
(Protocol #2000021153), and individual patient consent was waived, as this was a
retrospective analysis.

Ethics Statement
There were no ethical concerns related to this study, and the entirety of the study was
conducted in accordance with the approved protocol.

Patients
The study population included all patients who underwent TAVR for the treatment of
severe Aortic Stenosis with plan for conscious sedation at Yale New Haven Hospital (New
Haven, Connecticut) between September 2014 and December 2017. All patients were
evaluated by the Structural Heart Disease Team and were determined to be candidates for
TAVR rather than Surgical Aortic Valve Replacement (SAVR) based on standardized
assessment.

Data Collection
To identify patients in this cohort, D. Somlo requested patient medical record numbers
from the institutional Joint Data Analytics Team. Following review board approval of the
protocol, the Joint Data Analytics Team provided the record numbers and accompanying
data on patient demographics, comorbidities, procedure characteristics, and outcomes
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recorded for the Society of Thoracic Surgery (STS)/American College of Cardiology TVT
Registry. D. Somlo and Usman Bin Mahmood, MBBS, then completed manual chart
review using the healthcare system’s electronic medical record system, EPIC, to verify and
update all data using definitions from the STS/ACC TVT Registry v2.0 Coder’s Data
Dictionary. D. Somlo completed further chart review to clarify the cause of intraprocedural
conversion to general anesthesia, intraprocedural conversion to surgery, or hospital length
of stay greater than 3 days.

Mortality Data Collection
D. Somlo requested and obtained patient mortality data up to February 1, 2020 from both
chart review and from the Connecticut Department of Public Health. D. Somlo requested
records from the Connecticut Department of Public Health for January 2014 and December
2018. The state records were checked against each patient’s corresponding medical record
in EPIC to verify the mortality outcomes and dates. If a death was recorded in the state
records but not in EPIC, the state record was used. Conversely, if a patient was recorded
as deceased in EPIC but not in the state data, the EPIC data was used. 14 of the 60 deceased
patients (23%) were not recorded in the state records, because they were either not
Connecticut residents or passed after December 2018.

Risk Score Calculation
Of the 277 patients included in the analyses, 8 patients did not have STS Risk of Mortality
Scores in their charts. For these patients, D. Somlo calculated STS Risk of Mortality using
the online STS Calculator (version 2.9) by inputting the following variables obtained
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through chart review: age, sex, height, weight, current dialysis, hypertension,
immunocompromised status, prior peripheral arterial disease, prior cerebrovascular disease
or stroke, diabetes, chronic lung disease, smoking status, use of home oxygen, prior
Coronary Artery Bypass Grafting (CABG), prior Percutaneous Coronary Intervention
(PCI), prior aortic valve replacement, prior Myocardial Infarction, New York Heart
Association (NYHA) heart failure score from the prior 2 weeks, Coronary Artery Disease
(CAD) presenting symptoms, prior cardiogenic shock, pre-existing atrial fibrillation or
atrial flutter, pre-existing conduction defect, number of diseased coronary vessels, previous
permanent pacemaker, previous implantable cardioverter-defibrillator, status of TAVR
(elective, urgent, emergent), and prior cardiac arrest.

Dose calculations
To normalize medication doses for comparison, D. Somlo used the same approach as Chen
et al.42 First, chart review was completed to obtain total quantities of each medication
administered intraoperatively. Each medication quantity was then divided by each patient’s
mass (kg) and length of procedure (hours) to obtain dose in units of mcg/kg/hour or
mg/kg/hour.

Statistical Analysis and Figures
All statistical testing for this study was completed by D. Somlo, with assistance and support
from Makoto Mori, MD. Summary statistics of baseline patient characteristics, procedural
characteristics, and procedure outcomes and the multivariable linear and logistic regression
analysis were completed using GraphPad Prism version 9.0.0 (GraphPad Software, San

15

Diego, CA, United States). Cox proportional hazard analyses were completed in Stata 15.0
(StataCorp, College Station, TX, United States). An alpha of 0.05 was used as the cut-off
for significance, and all comparisons were two-sided. Descriptive statistics for continuous
variables were reported as mean with standard deviation, and categorical variables were
reported as count (percentage). For statistical comparison tests, continuous variables were
analyzed with ANOVA, and categorical variables were analyzed via Chi-square tests. For
comparisons of continuous variable distributions (cases over time, drug dose comparisons),
Kolmogorov-Smirnov tests were conducted. An outlier for length of stay was identified
using outlier analysis in GraphPad Prism (shown in Fig. 4). The outlier was only excluded
from regression analysis of hospital length of stay. All figures were generated by D. Somlo.
All figures were created using GraphPad Prism, with the exception of the Sankey diagram
(Fig.

1)

generated

using

(http://sankeymatic.com/build/).

free

online

software,

SankeyMATIC
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RESULTS
Patient CS medication groups are shown in Fig. 1. A total of 706 TAVR patients
were identified. 61% of patients (n=429) were treated with GA and were excluded. At the
study institution, CS is conducted by anesthesiology trainees and attending physicians for
TAVR. Per the American Society of Anesthesiologists, CS administered by an
anesthesiologist is referred to as “Monitored Anesthesia Care” (MAC), so CS will be
referred to as “MAC” for this study.

Figure 1: Sankey Diagram of patient exclusion and grouping. 272 of the 277 Conscious
Sedation patients were included in further analysis. Analyses A, B, and C examine different
combinations of the identified medication subgroups at the far right. MAC, Monitored
Anesthesia Care; Dex, Dexmedetomidine; Remifent., Remifentanil.

39% of TAVR cases (n=277) were completed under MAC. MAC patients were
treated with three main sedatives – propofol, midazolam, or dexmedetomidine – as well as
opioids (fentanyl and remifentanil). 5 of the 277 MAC patients were treated with unique
medications: hydromorphone (n=3), morphine (n=1), or ketamine (n=1). These 5 patients
were excluded from further analysis. Additionally, it was noted during chart review that
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many patients received lidocaine for local anesthesia, but lidocaine use and doses were not
considered. Three separate analyses were conducted from this pool of MAC patients to
assess characteristics and outcomes associated with different medication groups: Propofol
versus No Propofol (Analysis A), Propofol plus midazolam versus Propofol only (Analysis
B), and Dexmedetomidine versus No Dexmedetomidine (Analysis C).

Analysis A: Propofol versus No Propofol
272 CS patients were grouped based on whether or not they received propofol as
part of their MAC treatment. n=5 patients received a dose of propofol that was likely
subtherapeutic (<20mg total) and were excluded from both groups. The remaining 267
patients were divided into the Propofol group (n=203) and the No Propofol group (n=64).
Patient characteristics are reported in Table A1. The groups only differed significantly in
pre-operative permanent pacemaker (PPM), where the Propofol group had a lower rate of
pre-operative PPM (10.8% versus 23.4%; p = 0.021). To detect any era effect, the
distribution of cases by procedure date was examined. There was no significant difference
in the distribution of cases over time between the groups (Kolmogorov-Smirnov test, p =
0.19, Fig. 2).
Table A1 - Propofol vs. No Propofol
Baseline Patient Characteristics
Age (years)
Male sex
BMI (kg/m2)
STS Risk of Mortality Score
Hypertension
Diabetes
Currently on dialysis
Peripheral arterial disease
Cerebrovascular disease/TIA

Propofol group
(n=203)
82.5 ± 8.1
111 (54.7%)
28.0 ± 5.6
6.2 ± 3.9
175 (86.2%)
70 (34.5%)
5 (2.5%)
38 (18.7%)
19 (9.4%)

No Propofol
group (n=64)
83.0 ± 8.8
38 (59.4%)
28.9 ± 6.3
6.6 ± 5.0
54 (84.3%)
26 (40.6%)
1 (1.6%)
10 (15.6%)
5 (7.8%)

P Value
0.68
0.56
0.27
0.56
0.69
0.38
>0.99
0.71
0.81
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Prior Stroke
17 (8.4%)
5 (7.8%)
>0.99
Immunocompromised
28 (13.8%)
3 (9.7%)
0.07
Chronic lung disease
37 (18.2%)
8 (12.5%)
0.34
Current or former smoker
126 (62.1%)
36 (56.3%)
0.46
Home oxygen
12 (5.9%)
1 (1.6%)
0.20
Atrial fibrillation
71 (35.0%)
23 (35.9%)
0.88
Atrial flutter
8 (3.9%)
5 (7.8%)
0.31
Conduction defect
55 (27.1%)
20 (31.3%)
0.53
Permanent pacemaker
22 (10.8%)
15 (23.4%)
0.02 *
Diseased coronary vessels - none
90 (44.3%)
25 (39.1%)
Diseased coronary vessels - 1
49 (24.1%)
14 (21.9%)
0.17
Diseased coronary vessels - 2
37 (18.2%)
9 (14.1%)
Diseased coronary vessels - 3
27 (13.3%)
16 (25%)
Diseased proximal LAD
51 (25.1%)
23 (35.9%)
0.11
Diseased left main coronary artery
16 (7.9%)
11 (17.2%)
0.054
Prior myocardial infarction
55 (27.1%)
13 (20.3%)
0.33
Prior PCI
70 (34.5%)
23 (35.9%)
0.88
Prior coronary artery bypass
46 (22.7%)
18 (29.7%)
0.32
NYHA Class II
29 (14.3%)
14 (21.9%)
NYHA Class III
148 (72.9%)
44 (68.8%)
0.31
NYHA Class IV
26 (12.8%)
6 (9.4%)
Prior aortic valve replacement
18 (8.9%)
3 (4.7%)
0.42
Elective procedure
188 (92.6%)
60 (93.75%)
>0.99
Urgent procedure
15 (7.4%)
4 (6.25%)
No anginal symptoms
172 (84.7%)
54 (84.4%)
Angina, NSTEMI, STEMI
10 (4.9%)
3 (4.7%)
0.99
Likely non-ischemic symptoms
21 (10.3%)
7 (10.9%)
Pre-procedure hemoglobin (g/dL)
11.9 ± 1.7
11.9 ± 2.1
0.90
Pre-procedure creatinine (mg/dL)
1.2 ± 0.9
1.1 ± 0.3
0.13
Pre-procedure platelets (per µL)
210k ± 93k
209k ± 78k
0.90
TAVR, Transcatheter Aortic Valve Replacement; CS, Conscious Sedation; BMI, Body Mass Index; STS,
Society of Thoracic Surgeons; TIA, Transient Ischemic Attack; LAD, Left Anterior Descending coronary
artery; PCI, Percutaneous Coronary Intervention; NYHA Class, New York Heart Association classification
of heart failure; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial
infarction.
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Figure 2: TAVR Cases over
time for Propofol versus No
Propofol. Absolute case numbers
varied over time in both groups,
but the distributions of cases
were not significantly different
(Kolmogorov-Smirnov test, p =
0.19).
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Procedural characteristics are presented in Table A2. All TAVR procedures were
completed from a femoral entry site, via either percutaneous or cut-down access. 2% of
procedures in the Propofol group were completed with cutdown access, and none of
procedures in the No Propofol group were completed with cutdown (p = 0.58, Table A2).
A significantly lower percentage of Propofol group was treated with dexmedetomidine
(21.7% versus 65.6%, p <0.0001) and with remifentanil (13.3% versus 40.6%, p <0.0001,
Table A2). To investigate whether medication doses also differed between the groups,
doses were calculated according to the method used by Chen et al.42 Doses of each
medication were plotted by group (Figure 3) B. Only remifentanil doses differed
significantly between the groups, where the Propofol group received lower doses of
remifentanil (mean dose 1.17 mcg/kg/hr versus 2.34 mcg/kg/hr, p = 0.0024).
Table A2 - Propofol vs. No Propofol
Summary Statistics of Procedural Characteristics
Valve-in-valve procedure
Percutaneous Access
Cutdown Access
Treated with propofol
Propofol dose (mg/kg/hr)
Treated with midazolam
Midazolam dose (mcg/kg/hr)
Treated with dexmedetomidine
Dexmedetomidine dose (mcg/kg/hr)
Treated with fentanyl
Fentanyl dose (mcg/kg/hr)
Treated with remifentanil
Remifentanil dose (mcg/kg/hr)

B

Propofol (n=203)
12 (5.9%)
199 (98%)
4 (2%)
203 (100%)
1.03 ± 0.7
79 (38.9%)
7.0 ± 3.9
42 (20.7%)
0.38 ± 0.2
171 (84.2%)
0.42 ± 0.3
27 (13.3%)
1.2 ± 1.0

No Propofol (n=64)
2 (3.1%)
64 (100%)
0
0
26 (40.6%)
6.8 ± 3.6
42 (65.6%)
0.41 ± 0.2
54 (84.4%)
0.42 ± 0.3
26 (40.6%)
2.3 ± 1.5

P Value
0.53
0.58
0.88
0.65
<0.0001 *
0.065
>0.99
0.56
<0.0001 *
0.002 *

Because the doses were normalized to anesthesia time rather than total medication infusion time, the

resulting doses are lower than what is expected from dosing guidelines for each medication.

20

ns

Dexmedetomidine Dose
(mcg/kg/hour)

Midazolam Dose
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Figure 3: Comparison of medication doses between the Propofol
versus No Propofol group. The Kolmogorov-Smirnov test was used to
compare doses. ns, Not signifcant.

Analysis A: Unadjusted outcomes
Unadjusted outcomes are shown in Table A3a. Total anesthesia time did not differ
significantly between the groups (202 versus 195 minutes, p = 0.27), and no procedures
were aborted. There were 2 conversions to GA, with 1 conversion in the Propofol group
(0.5%) and 1 in the No Propofol group (1.6%, p = 0.42). The patient who was converted to
GA in the Propofol group was an 84-year-old female who became hypotensive and
bradycardic during the procedure, requiring epinephrine and a brief period of
cardiopulmonary resuscitation. She was converted to GA when she was intubated for
stabilization. For the case in the No Propofol group, a 91-year-old male was noted to have
hypercarbia and converted to GA for intubation. No procedures were converted to surgical
valve replacement. There was no significant difference in in-hospital mortality (0.5%
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versus 1.6%, p = 0.42) or in discharge location (81.3% versus 79.7% discharged to home
or nursing home, p = 0.85).
Table A3a - Propofol vs. No Propofol
Unadjusted, Descriptive Statistics of Peri- and Postoperative Outcomes
Total anesthesia time (minutes)
Conversion to general anesthesia
Conversion to surgical replacement
Procedure aborted
Deceased in-hospital
Discharged to hospice
Home or nursing home
Rehab/extended care/
transitional care unit

Propofol (n=203)

No Propofol (n=64)

202 ± 45
1 (0.5%)
0
0
2 (1.0%)
1 (0.5%)
165 (81.3%)

195 ± 33
1 (1.6%)
0
0
1 (1.6%)
0
51 (79.7%)

35 (17.2%)

12 (18.8%)

P Value
0.27
0.42
0.42
>0.99
>0.99

Specific attention was paid to patients with prolonged LOS after TAVR (> 4 days),
which is associated with all-cause mortality and worse outcomes at 1-year post-TAVR.39
Chart review was conducted for patients with LOS > 4 days, and unadjusted results are
shown in Table A3b. There was no significant difference in the percentage of patients who
had prolonged LOS between the Propofol versus No Propofol groups, and there were no
significant associations between medication group and incidence of specific causes of
prolonged hospitalization.
Table A3b - Propofol vs. No Propofol (Patients with LOS > 4 days)
Unadjusted, Descriptive Statistics of Postoperative Complications
Incidence of LOS > 4 days
Fluid overload
Hypotension
Heart block
PPM Placement
Bleeding
Elevated creatinine
Infection
New arrhythmia
Delirium
Stroke

Propofol (n=43)

No Propofol (n=13)

43 (21.2%)
13 (30.2%)
12 (27.9%)
12 (27.9%)
11 (25.6%)
9 (20.9%)
8 (18.6%)
8 (18.6%)
4 (9.3%)
4 (9.3%)
3 (7.0%)

13 (20.3%)
6 (46.2%)
3 (23.1%)
5 (38.5%)
5 (38.5%)
3 (23.1%)
2 (15.4%)
2 (15.4%)
1 (7.7%)
1 (7.7%)
0

P value
>0.99
0.33
>0.99
0.50
0.49
>0.99
>0.99
>0.99
>0.99
>0.99
>0.99
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Hypertension
TIA
Urinary retention
Diarrhea
Pseudogout
Limb ischemia

3 (7.0%)
2 (4.7%)
2 (4.7%)
1 (2.3%)
1 (2.3%)
1 (2.3%)

0
0
1 (7.7%)
1 (7.7%)
0
0

>0.99
>0.99
0.55
0.41
>0.99
>0.99

Analysis A: Adjusted Outcomes
Linear regression analysis was conducted to adjust for the significantly different
baseline characteristics when assessing for association between the Propofol group and
continuous variable outcomes. Results are shown in Table A4. One patient in the Propofol
group had a LOS of 32 days (shown in Fig. 4) and was excluded as an outlier from the LOS
analysis. When controlling for pre-operative PPM, treatment with dexmedetomidine, and
remifentanil dose, the Propofol group was not significantly associated with a change in
hospital LOS (Coefficient 0.5 days, 95%CI: [-0.2, 1.2], p = 0.15), change in creatinine from
pre- to post-procedure (Coefficient 0.04 mg/dL, 95%CI: [-0.1, 0.2], p = 0.60), change in
hemoglobin pre- to post-procedure (Coefficient -0.4 g/dL, 95%CI: [-0.9, 0.06], p = 0.084),
or creatinine at discharge (Coefficient 0.24 mg/dL, 95%CI: [-0.03, 0.5], p = 0.09).
Table A4 - Propofol vs. No Propofol
Linear Regression Analyses
Regression
Outcome
Hospital length of
stay (days) (one
outlier excluded
from Propofol
group)

Variable

Coefficient

95% CI

Propofol (versus No Propofol)
Pre-op Permanent Pacemaker
Treated with Dexmedetomidine

0.498
-0.104
0.464

-0.175, 1.170
-0.788, 0.580
-0.102, 1.030

0.15
0.76
0.11

Remifentanil Dose, mcg/kg/hr

-0.079

-0.359, 0.202

0.58

Change in
Creatinine, pre to
post-procedure
(mg/dL)

Propofol
Pre-op Permanent Pacemaker
Treated with Dexmedetomidine
Remifentanil Dose, mcg/kg/hr

0.038
-0.041
0.046
-0.028

-0.104, 0.180
-0.186, 0.104
-0.074, 0.166
-0.087, 0.031

0.60
0.57
0.45
0.35

Change in
Hemoglobin, pre to
post-procedure
(g/dL)

Propofol
Pre-op Permanent Pacemaker
Treated with Dexmedetomidine
Remifentanil Dose, mcg/kg/hr

-0.415
-0.030
-0.211
-0.186

-0.887, 0.057
-0.510, 0.450
-0.608, 0.186
-0.383, 0.011

0.084
0.90
0.30
0.064

P Value
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Creatinine at
discharge (mg/dL)

Propofol
Pre-op Permanent Pacemaker
Treated with Dexmedetomidine
Remifentanil Dose, mcg/kg/hr

LOS (Days)

30

-0.035, 0.513
-0.286, 0.270
-0.080, 0.379
-0.099, 0.131

0.09
0.95
0.20
0.78

Figure 4: Comparison of length of stay
for all MAC patients. All MAC cases
(n=272) were plotted by total LOS. One
outlier was identified (blue dot, LOS = 32
days). This outlier was a patient who was
treated with propofol and midazolam, and
this patient was excluded from regression
analysis for LOS in Analysis A, B, and C.
Excluding the outlier: mean LOS, 2.9 days;
Standard Deviation, 1.9 days. Median LOS,
2.0 days; Interquartile Range 2.0-3.0 days.
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Logistic regression analysis was used to assess the association of the Propofol
group with binary outcomes while adjusting for different baseline characteristics.
Regression results are shown in Table A5. Inclusion in the Propofol group was not
significantly associated with incidence of post-operative PPM (Odds Ratio 3.4, 95%CI:
[0.3, 91.6], p = 0.36, Table A5) or need for red blood cell (RBC) transfusion postoperatively (OR 1.1, 95%CI: [0.3, 5.0], p = 0.89). For the analysis of post-operative PPM,
37 patients were excluded, because they had pre-operative PPMs (Propofol group n=22,
10.8% versus n=15, 23.4%, Table A1). Lastly, Cox proportional hazard analysis was used
to test for any association of MAC medication group with mortality while adjusting for
baseline differences. Results are shown in Table A6. There was no significant association
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between the Propofol group and mortality compared to the No Propofol group (Hazard
Ratio 1.1, 95%CI: [0.5, 2.3], p = 0.81, Table A6).
Table A5 - Propofol vs. No Propofol
Logistic Regression Analyses
Regression
Outcome
Post-operative PPM,
excluding preexisting PPM (n=
230)

RBC transfusion

Variable

Odds
Ratio

95% CI

Propofol (versus No Propofol)
Treated with Dexmedetomidine

0.733
0.706

0.242, 2.312
0.260, 1.729

0.58
0.47

Remifentanil Dose, mcg/kg/hr

0.674

0.328, 1.115

0.19

Propofol
Pre-op Permanent Pacemaker
Treated with Dexmedetomidine
Remifentanil Dose, mcg/kg/hr

1.105
1.135
0.731
0.966

0.286, 4.991
0.249, 3.749
0.203, 2.213
0.470, 1.617

0.89
0.85
0.60
0.91

Hazard
Ratio

95% CI

1.095
0.579
1.382
0.867

0.527, 2.276
0.243, 1.378
0.771, 2.475
0.596, 1.262

Table A6 - Propofol vs. No Propofol
Cox Proportional Hazard Model Outcomes
Regression
Outcome

Mortality

Variable
Propofol (versus No Propofol)
Pre-op Permanent Pacemaker
Treated with Dexmedetomidine
Remifentanil Dose, mcg/kg/hr

P Value

P Value
0.81
0.22
0.28
0.46

Analysis B: Propofol plus midazolam versus Propofol only
The Propofol plus midazolam group (n=70) and Propofol only group (n=94) were
isolated for the second analysis. Patient characteristics are reported in Table B1. There
were several characteristics that were significantly different between groups: the Propofol
plus midazolam group was younger (78.8 ± 8.3 years versus 85.9 ± 6.0 years; p < 0.0001),
had higher body mass index (BMI, 30.0 ± 5.7 versus 27.1 ± 5.1; p = 0.0009), had a lower
mean STS Risk of Mortality Score (5.3 ± 3.7 versus 6.4 ± 5.3; p = 0.039), lower prevalence
of atrial fibrillation (25.7% versus 48.9%; p = 0.004), and higher prevalence of previous
myocardial infarction (35.7% versus 17.0%; p = 0.01). There was no significant difference
in the distribution of cases over time (p = 0.27, Fig. 5).
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Table B1 - Propofol plus midazolam vs. Propofol only
Baseline Patient Characteristics
Age (years)
Male sex
BMI (kg/m2)
STS Risk of Mortality Score
Hypertension
Diabetes
Currently on dialysis
Peripheral arterial disease
Cerebrovascular disease/TIA
Prior Stroke
Immunocompromised
Chronic lung disease
Current or former smoker
Home oxygen
Atrial fibrillation
Atrial flutter
Conduction defect
Permanent pacemaker
Diseased coronary vessels - none
Diseased coronary vessels - 1
Diseased coronary vessels - 2
Diseased coronary vessels - 3
Diseased proximal LAD
Diseased left main coronary artery
Prior myocardial infarction
Prior PCI
Prior coronary artery bypass
NYHA Class II
NYHA Class III
NYHA Class IV
Prior aortic valve replacement
Elective procedure
Urgent procedure
No anginal symptoms
Angina, NSTEMI, STEMI
Likely non-ischemic symptoms
Pre-procedure hemoglobin (g/dL)
Pre-procedure creatinine (mg/dL)
Pre-procedure platelets (per µL)

Propofol plus midazolam
(n=70)
78.8 ± 8.3
41 (44.1%)
30.0 ± 5.7
5.3 ± 3.7
62 (88.6%)
29 (41.4%)
0
9 (12.9%)
8 (11.4%)
5 (7.1%)
10 (14.3%)
11 (15.7%)
46 (65.7%)
4 (5.7%)
18 (25.7%)
4 (5.7%)
14 (20.0%)
4 (5.7%)
32 (45.7%)
19 (27.1%)
9 (12.9%)
10 (14.3%)
19 (27.1%)
5 (7.1%)
25 (35.7%)
22 (31.4%)
18 (25.7%)
15 (21.4%)
47 (67.1%)
8 (11.4%)
6 (8.6%)
64 (91.4%)
6 (8.6%)
58 (82.9%)
7 (10%)
5 (7.1%)
12.1 ± 1.6
1.2 ± 0.6
205k ± 97k

Propofol only
(n=94)
85.9 ± 6.0
52 (55.9%)
27.1 ± 5.1
6.4 ± 5.3
78 (83.0%)
25 (26.6%)
2 (2.1%)
15 (16.0%)
7 (7.5%)
5 (5.3%)
11 (11.7%)
18 (19.2%)
55 (58.5%)
3 (3.2%)
46 (48.9%)
3 (3.2%)
30 (31.2%)
14 (14.9%)
41 (43.6%)
21 (22.3%)
18 (19.1%)
14 (14.9%)
26 (27.6%)
7 (7.5%)
16 (17.0%)
36 (38.3%)
17 (18.1%)
10 (10.6%)
71 (75.5%)
13 (13.8%)
8 (8.5%)
88 (93.6%)
6 (6.4%)
80 (85.1%)
10 (10.6%)
4 (4.3%)
11.7 ± 1.8
1.2 ± 0.8
209k ± 88k

P Value
<0.0001*
0.75
0.0009 *
0.04 *
0.38
0.064
0.51
0.66
0.42
0.75
0.64
0.68
0.42
0.46
0.004 *
0.46
0.11
0.08
0.70
>0.99
>0.99
0.01 *
0.41
0.25
0.16
>0.99
0.76
0.72
0.17
0.99
0.76
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Figure 5: TAVR Cases over
time for Propofol plus
Midazolam versus Propofol.
The distributions of cases
over time were not
significantly different
(Kolmogorov-Smirnov test, p
= 0.27).
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Procedural characteristics are presented in Table B2. Cutdown procedures were
only conducted in the Propofol group (n=2, 2.1%, p = 0.51). A significantly lower
percentage of patients in the Propofol plus midazolam group were treated with remifentanil
(8.6% versus 22.3%; p = 0.02, Table B2), and the Propofol plus midazolam group was
treated with a significantly higher dose of fentanyl (mean dose 0.52 mcg/kg/hr versus 0.35
mcg/kg/hr, p = 0.0002, Fig. 6). All other medications and doses were not significantly
different.
Table B2 – Propofol plus midazolam vs. Propofol
Summary Statistics of Procedural Characteristics
Valve-in-valve procedure
Percutaneous Access
Cutdown Access
Treated with propofol
Propofol dose (mg/kg/hr)
Treated with midazolam
Midazolam dose (mcg/kg/hr)
Treated with fentanyl
Fentanyl dose (mcg/kg/hr)
Treated with remifentanil
Remifentanil dose (mcg/kg/hr)

Propofol plus
midazolam (n=70)
3 (4.3%)
70 (100%)
0
70 (100%)
1.0 ± 0.7
70 (100%)
7.1 ± 4.0
63 (90%)
0.52 ± 0.2
6 (8.6%)
1.2 ± 1.4

Propofol
(n=94)
6 (6.4%)
92 (97.9%)
2 (2.1%)
94 (100%)
1.1 ± 0.7
0
78 (83.0%)
0.35 ± 0.2
21 (22.3%)
1.2 ± 0.9

P Value
0.73
0.51
0.18
0.26
0.0002 *
0.02 *
0.84
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Figure 6: Comparison of medication doses between Propofol plus Midazolam
versus Propofol only. The Kolmogorov-Smirnov test was used to compare doses.
ns, not significant; Prop, Propofol.

Analysis B: Unadjusted outcomes
Unadjusted procedure outcomes are shown in Table B3a. Total anesthesia time was
not significantly different between the groups. There was 1 conversion to GA in the
Midazolam plus Propofol group (1.4%), and there was no significant difference in inhospital mortality (1.4% versus 1.1%, p > 0.99). There was also no difference in discharge
locations between the groups (82.9% versus 79.8% discharged to home or nursing home,
p = 0.53).
Table B3a – Propofol plus midazolam vs. Propofol only
Unadjusted, Descriptive Statistics of Peri- and Postoperative Outcomes
Total anesthesia time (minutes)
Conversion to general anesthesia
Conversion to surgical replacement
Procedure aborted
Deceased in-hospital
Discharged to hospice
Discharged to home or nursing home
Discharged to rehab/extended
care/transitional care unit

Propofol plus midazolam
(n=70)
197 ± 42
1 (1.4%)
0
0
1 (1.4%)
1 (1.4%)
58 (82.9%)

Propofol only
(n=94)
200 ± 41
0
0
0
1 (1.1%)
0
75 (79.8%)

10 (14.3%)

12 (12.8%)

P Value
0.71
0.43
>0.99
0.43
>0.99
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Analysis of patients with LOS > 4 days is shown in Table B3b. The Propofol plus
midazolam group had a lower percent of patients with LOS > 4 days, but the difference
was not significant (12.9% versus 24.5%, p = 0.075, Table B3b). Since this analysis was
unadjusted, the association between the medication groups and prolonged LOS was also
tested using logistic regression to adjust for different baseline variables (Table B5). In the
adjusted analysis, the association remained non-significant (Odds Ratio 0.85, 95%CI: [0.3,
2.4], p = 0.78). Additionally, the Propofol plus midazolam group had a higher percentage
of patients who experienced hypotension as part of the cause of their prolonged length of
stay (55.5% versus 17.4%, p = 0.075, Table B3b). This association was also tested with
adjustment (Table B5), and the association remained non-significant (Odds Ratio 5.8,
95%CI: [0.6, 81.6], p = 0.14, Table B5).
Table B3b – Propofol plus midazolam vs. Propofol only (Patients with LOS > 4 days)
Unadjusted, Descriptive Statistics of Postoperative Complications
Incidence of LOS > 4 days
Hypotension
Fluid overload
Elevated creatinine
Heart block
PPM Placement
Infection
Stroke
Bleeding
Hypertension
Delirium
Limb ischemia
New arrhythmia
Urinary retention
TIA
Diarrhea

Propofol plus midazolam
(n=9)
9 (12.9%)
5 (55.5%)
3 (33.3%)
3 (33.3%)
3 (33.3%)
3 (33.3%)
2 (22.2%)
2 (22.2%)
1 (11.1%)
1 (11.1%)
1 (11.1%)
1 (11.1%)
0
0
0
0

Propofol only
(n=23)
23 (24.5%)
4 (17.4%)
5 (21.8%)
3 (13.0%)
6 (26.1%)
5 (21.8%)
4 (17.4%)
1 (4.3%)
6 (26.1%)
2 (8.7%)
1 (4.3%)
0
2 (8.7%)
2 (8.7%)
1 (4.3%)
1 (4.3%)

P Value
0.075
0.075
0.65
0.31
0.69
0.65
>0.99
0.18
0.64
>0.99
0.49
0.28
>0.99
>0.99
>0.99
>0.99
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Analysis B: Adjusted Outcomes
The effect of the medication groups on continuous variable outcomes was assessed
using linear regression analysis to control for significantly different baseline
characteristics. Regression results are shown in Table B4. One patient in the Propofol plus
midazolam group had a LOS of 32 days and was excluded as an outlier (shown previously
in Fig. 4). Compared to the Propofol only group, Propofol plus midazolam was not
associated with LOS (Coefficient 0.2 days, 95%CI: [-0.5, 0.8], p = 0.62), change in
creatinine (Coefficient -0.02 mg/dL, 95%CI: [-0.2, 0.1], p = 0.85), change in hemoglobin
(Coefficient -0.06 g/dL, 95%CI: [-0.5, 0.7], p = 0.64), or creatinine at discharge
(Coefficient -0.04 mg/dL, 95%CI: [-0.3, 0.2], p = 0.76). Conversely, other variables in the
model were significantly association with several outcomes. First, a 1% increase in STS
Risk Score was associated with a 0.13 day increased in LOS (Coefficient 0.13 days,
95%CI: [0.05, 0.2], p = 0.002). Second, a 1 kg/m2 increase in body mass index (BMI) was
associated with a 0.015 mg/dL increase in creatinine post-operatively (Coefficient 0.015
mg/dL, 95%CI: [0.003, 0.03], p = 0.016) and a 0.028 mg/dL increase in discharge
creatinine (Coefficient 0.028 mg/dL, 95%CI: [0.008, 0.048], p = 0.007).
Table B4 - Propofol plus midazolam vs. Propofol only
Linear Regression Analyses
Regression
Outcome

Hospital length
of stay (days)
(1 outlier
removed from
Propofol plus
midazolam
group)
Change in
Creatinine, pre to

Variable

Coefficient

95% CI

P Value

Propofol plus midazolam
(versus Propofol only)
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)

0.169

-0.506, 0.843

0.62

0.021
0.003
0.126
-0.095
-0.278
0.459
-0.575

-0.019, 0.062
-0.048, 0.055
0.047, 0.206
-0.666, 0.476
-0.919, 0.364
-0.309, 1.226
-1.783, 0.633

0.31
0.90
0.002 *
0.74
0.39
0.24
0.35

Propofol plus midazolam
Age

-0.016
-0.0002

-0.177, 0.145
-0.010, 0.010

0.85
0.96
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post-procedure
(mg/dL)

Change in
Hemoglobin, pre
to postprocedure (g/dL)

Creatinine at
discharge
(mg/dL)

BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)

0.015
0.011
-0.052
0.048
0.009
0.029

0.003, 0.028
-0.008, 0.030
-0.189, 0.085
-0.105, 0.202
-0.175, 0.193
-0.259, 0.317

0.016 *
0.25
0.46
0.53
0.92
0.84

Propofol plus midazolam
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)

0.063
-0.026
-0.027
0.035
0.326
0.004
-0.546
0.002

-0.526, 0.652
-0.062, 0.010
-0.073, 0.0182
-0.035, 0.105
-0.176, 0.827
-0.558, 0.566
-1.220, 0.129
-1.053, 1.057

0.83
0.16
0.24
0.33
0.20
0.99
0.11
0.99

Propofol plus midazolam
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)

-0.040
-0.004
0.028
0.028
0.030
-0.047
-0.007
-0.133

-0.304, 0.224
-0.020, 0.012
0.008, 0.048
-0.004, 0.059
-0.195, 0.255
-0.299, 0.204
-0.312, 0.298
-0.606, 0.339

0.76
0.61
0.007 *
0.08
0.79
0.71
0.96
0.58

Logistic regression analysis was used to assess for association between Propofol
plus midazolam and binary outcomes of interest. Regression results are shown in Table B5.
Propofol plus midazolam was not significantly associated with post-operative PPM (Odds
Ratio 1.0, 95%CI: [0.3, 3.1], p = 0.94) or with RBC transfusion (OR 1.2, 95%CI: [0.3, 5.0],
p = 0.83). 18 patients had pre-operative permanent PPMs and were excluded from the
analysis of post-operative PPM (n=4, 5.7% and n=14, 14.9%, p = 0.08, Table B1).
However, there was a significant association between STS Risk Score and post-operative
RBC transfusion (OR 1.2, 95%CI: [1.05, 1.40], p = 0.008). Additionally, STS Risk Score
was associated with increased odds of LOS > 4 days (OR 1.21, 95%CI: [1.07, 1.34], p =
0.004, Table B5).
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Table B5 - Propofol plus midazolam vs. Propofol only
Logistic Regression Analyses
Outcome

Post-operative PPM,
excluding preexisting PPM (n=
164)

RBC transfusion

Length of stay > 4
days (Prolonged
LOS)

Hypotension
(amongst patients
with prolonged
LOS, n=9 versus
n=23) †

Variable

Propofol plus midazolam
(versus Propofol only)
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)
Propofol plus midazolam
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)
Propofol plus midazolam
(versus Propofol only)
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)
Propofol plus midazolam
(versus Propofol only)
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction

Odds Ratio

95% CI

P Value

1.041

0.336, 3.137

0.94

0.990
1.044
0.977
0.843
1.049
1.068
0.732
1.176
1.019
1.065
1.205
0.400
1.333
3.818
0.499

0.928, 1.059
0.962, 1.134
0.830, 1.113
0.305, 2.192
0.330, 3.007
0.262, 3.677
0.091, 4.996
0.256, 5.023
0.936, 1.118
0.950, 1.196
1.054, 1.401
0.093, 1.414
0.314, 4.983
0.894, 15.93
0.030, 6.330

0.76
0.30
0.76
0.73
0.93
0.92
0.76
0.83
0.67
0.28
0.008 *
0.18
0.68
0.063
0.61

0.845

0.279, 2.417

0.78

1.012
0.983
1.205
0.550
0.422
2.460
0.285

0.947, 1.085
0.904, 1.067
1.068, 1.377
0.210, 1.359
0.112, 1.283
0.842, 7.027
0.033 2.035

0.73
0.69
0.004 *
0.21
0.16
0.09
0.23

5.790

0.632, 81.60

0.14

0.920
0.940
0.842
0.236
0.636

0.790, 1.056
0.740, 1.148
0.592, 1.065
0.011, 2.091
0.009, 22.73

0.23
0.56
0.25
0.24
0.82

Input variables for Remifentanil treatment and Fentanyl dose were removed, because the model did not
converge.
†

Cox proportional hazard analysis found no association between the Propofol plus
midazolam group and mortality compared to the Propofol only group (Hazard Ratio 0.5,
95%CI: [0.2, 1.2], p = 0.13). Other variables did demonstrate significant association with
mortality: 1% increase in STS Risk score was associated with a 12% increase in hazard of
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death (HR 1.12, 95%CI: [1.0, 1.2], p = 0.003), and atrial fibrillation was associated with a
128% increase in hazard of death (HR 2.28, 95%CI: [1.1, 4.8], p = 0.03).
Table B6 - Propofol plus midazolam vs. Propofol only
Cox Proportional Hazard Model Outcomes
Outcome

Mortality

Variable
Propofol plus midazolam
Age
BMI
STS Risk Score
Atrial fibrillation
Prior myocardial infarction
Treated with Remifentanil
Fentanyl Dose (mcg/kg/hr)

Hazard
Ratio

95% CI

P Value

0.510
1.049
1.031
1.120
2.277
0.935
1.148
0.566

0.212, 1.226
0.991, 1.111
0.962, 1.104
1.039, 1.206
1.079, 4.801
0.413, 2.117
0.461, 2.862
0.107, 2.982

0.13
0.10
0.39
0.003 *
0.03 *
0.87
0.77
0.50

Analysis C: Dexmedetomidine versus No Dexmedetomidine
Lastly, the 272 CS patients were divided into the Dexmedetomidine group (n=86)
and the No Dexmedetomidine group (n=186). Patient characteristics are reported in Table
C1. The groups only differed significantly in incidence of peripheral arterial disease, where
the Dexmedetomidine group had significantly more disease burden (26.7% versus 13.4%;
p = 0.01). Additionally, the case distribution over time differed significantly between the
groups (p < 0.0001, Fig. 7), indicating that the procedure year needs to be taken into
account as a potential confounding variable.
Table C1 - Dexmedetomidine vs. No Dexmedetomidine group
Baseline Characteristics of TAVR Patients
Age (years)
Male sex
BMI (kg/m2)
STS Risk of Mortality Score
Hypertension
Diabetes
Currently on dialysis
Peripheral arterial disease

Dexmedetomidine
(n=86)
82.3 ± 8.7
46 (53.5%)
27.6 ± 6.2
6.4 ± 4.0
74 (87.2%)
34 (39.5%)
4 (4.7%)
23 (26.7%)

No Dex
(n=186)
83.0 ± 8.0
107 (57.5%)
28.5 ± 5.6
6.2 ± 4.1
157 (84.4%)
62 (33.3%)
2 (1.1%)
25 (13.4%)

P Value
0.52
0.60
0.28
0.72
0.59
0.34
0.08
0.01 *
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Cerebrovascular disease/TIA
Prior Stroke
Immunocompromised
Chronic lung disease
Current or former smoker
Home oxygen
Atrial fibrillation
Atrial flutter
Conduction defect
Permanent pacemaker
Diseased coronary vessels - none
Diseased coronary vessels - 1
Diseased coronary vessels - 2
Diseased coronary vessels - 3
Diseased proximal LAD
Diseased left main coronary artery
Prior myocardial infarction
Prior PCI
Prior coronary artery bypass
NYHA Class II
NYHA Class III
NYHA Class IV
Prior aortic valve replacement
Elective procedure
Urgent procedure
No anginal symptoms
Angina, NSTEMI, STEMI
Likely non-ischemic symptoms
Pre-procedure hemoglobin (g/dL)
Pre-procedure creatinine (mg/dL)
Pre-procedure platelets (per µL)
40

Cases
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8 (9.3%)
11 (12.8%)
8 (9.3%)
13 (15.1%)
51 (59.3%)
6 (7.0%)
26 (30.2%)
5 (5.8%)
27 (31.4%)
14 (16.3%)
36 (41.9%)
15 (17.4%)
18 (20.9%)
17 (19.8%)
24 (27.9%)
12 (14.0%)
22 (25.6%)
28 (32.6%)
27 (31.4%)
14 (16.3%)
66 (76.7%)
6 (7.0%)
5 (5.8%)
82 (95.3%)
4 (4.7%)
75 (87.2%)
3 (3.5%)
8 (9.3%)
12.1 ± 1.9
1.2 ± 1.0
221k ± 85k

Dexmedetomidine
No Dex

20
10

>0.99
0.10
0.54
0.73
0.89
0.36
0.22
0.56
0.56
0.46
0.30
>0.99
0.13
0.88
0.68
0.07
0.23
0.48
0.44
0.73
0.30
0.63
0.18

Figure 7: TAVR Cases over
time, Dexmedetomidine
versus No Dexmedetomidine.
The distributions of cases over
time significantly different
(Kolmogorov-Smirnov test, p
<0.0001).
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0

17 (9.1%)
12 (6.5%)
23 (12.4%)
32 (12.7%)
113 (60.8%)
7 (3.8%)
71 (38.2%)
8 (4.3%)
51 (27.4%)
24 (12.9%)
81 (43.5%)
48 (25.8%)
31(16.7%)
26 (13.4%)
53 (28.5%)
15 (8.1%)
46 (24.7%)
66 (35.5%)
39 (21.0%)
31 (16.7%)
129 (69.4%)
26 (14.0%)
16 (8.6%)
171 (91.9%)
15 (8.1%)
156 (83.9%)
10 (5.4%)
20 (10.8%)
11.8 ± 1.8
1.2 ± 0.7
205k ± 91k

Procedural characteristics are presented in Table C2. Cutdown access occurred in
both groups (2.3% versus 1.1%, p = 0.59). Several other procedural characteristics were
significantly different: fewer patients in the Dexmedetomidine group were treated with
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propofol (50% versus 88.2%, p <0.0001) and remifentanil (13.3% versus 40.6%, p
<0.0001), and propofol doses were significantly lower in the Dexmedetomidine group
(mean dose 0.76 mcg/kg/hr versus 1.1 mcg/kg/hr, p = 0.0024, Fig. 8).
Table C2 – Dexmedetomidine vs. No Dexmedetomidine group
Summary Statistics of TAVR Procedural Characteristics
Dexmedetomidine
(n=86)
4 (4.7%)
84 (97.7%)
2 (2.3%)
43 (50%)
0.76 ± 0.7
25 (29.1%)
6.7 ± 3.5
86 (100%)
0.40 ± 0.2
68 (79.1%)
0.41 ± 0.3
13 (15.1%)
1.7 ± 1.3

Valve-in-valve procedure
Percutaneous Access
Cutdown Access
Treated with propofol
Propofol dose (mg/kg/hr)
Treated with midazolam
Midazolam dose (mcg/kg/hr)
Treated with dexmedetomidine
Dexmedetomidine dose (mcg/kg/hr)
Treated with fentanyl
Fentanyl dose (mcg/kg/hr)
Treated with remifentanil
Remifentanil dose (mcg/kg/hr)

p = 0.006

3
2
1
0

Dex

ns

2.0
1.5
1.0
0.5
0.0

Dex

15
10
5
Dex

8

Remifentanil Dose
(mcg/kg/hour)

Fentanyl Dose
(mcg/kg/hour)

2.5

No Dex

>0.99
0.59
<0.0001 *
0.006 *
0.10
0.70
0.10
0.08
0.19
0.94

20

0

No Dex

P Value

ns

25

✱✱

Midazolam Dose
(mcg/kg/hour)

Propofol Dose
(mg/kg/hour)

4

No Dex
(n=186)
10 (5.4%)
184 (98.9%)
2 (1.1%)
164 (88.2%)
1.1 ± 0.7
74 (39.8%)
7.1 ± 4.0
0
162 (87.1%)
0.42 ± 0.2
42 (22.6%)
1.8 ± 1.4

No Dex

ns

6
4
2
0

Dex

No Dex

Figure 8:
Comparison of
medication doses
between the
Dexmedetomidine
versus No
Dexmedetomidine
groups. The
Kolmogorov-Smirnov
test was used to
compare doses. ns, not
significant; Dex,
Dexmedetomidine.
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Analysis C: Unadjusted outcomes
Unadjusted procedure outcomes are shown in Table C3a. Total anesthesia time
did not differ significantly between the groups (204 minutes versus 198, p = 0.25). No
patients were converted to GA in the Dexmedetomidine group, and 2 were converted in
the No Dexmedetomidine group (p > 0.99). There was no difference in in-hospital
mortality (1.2% versus 0.5%, p = 0.53) or in discharge location (81.4% discharged to
home or nursing home versus 81.4%, p > 0.99). There was also no difference in the
percent of patients who experienced prolonged LOS (23.3% versus 19.9%, p = 0.53,
Table C3b), and there were no differences in the incidence of specific causative
complications.
Table C3a – Dexmedetomidine vs. No Dexmedetomidine
Unadjusted, Descriptive Statistics of Peri- and Postoperative Outcomes
Total anesthesia time (minutes)
Conversion to general anesthesia
Conversion to surgical replacement
Procedure aborted
Deceased in-hospital
Discharged to hospice
Discharged to home or nursing home
Discharged to rehab/extended
care/transitional care unit

Dexmedetomidine
(n=86)

No Dexmedetomidine
(n=186)

204 ± 48
0
0
0
1 (1.2%)
0
70 (81.4%)

198 ± 40
2 (1.1%)
0
0
2 (1.1%)
2 (1.1%)
149 (80.1%)

15 (17.4%)

34 (18.3%)

P Value
0.25
>0.99
>0.99
>0.99

Table C3b – Dexmedetomidine vs. No Dexmedetomidine (Patients with LOS > 4 days)
Unadjusted, Descriptive Statistics of Postoperative Complications
Incidence of LOS > 4 days
Hypotension
Fluid overload
Elevated creatinine
Heart block
PPM Placement
Infection
Stroke
Bleeding

Dexmedetomidine
(n=20)
20 (23.3%)
4 (20%)
9 (45%)
3 (15%)
6 (30%)
6 (30%)
3 (15%)
1 (5%)
5 (25%)

No Dexmedetomidine
(n=37)
37 (19.9%)
11 (29.7%)
10 (27.0%)
7 (18.9%)
11 (29.7%)
10 (27.0%)
7 (18.9%)
3 (8.1%)
8 (21.6%)

P Value
0.53
0.54
0.24
>0.99
>0.99
>0.99
>0.99
>0.99
0.75
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Hypertension
Delirium
New arrhythmia
Pseudogout
Diarrhea
Urinary retention
TIA
Limb ischemia

1 (5%)
3 (15%)
3 (15%)
1 (5%)
1 (5%)
0
0
0

2 (5.4%)
2 (5.4%)
2 (5.4%)
0
1 (2.7%)
3 (8.1%)
1 (2.7%)
1 (2.7%)

>0.99
0.33
0.33
0.35
>0.99
0.54
>0.99
>0.99

Analysis C: Adjusted Outcomes
Linear regression was used to assess for association between the Dexmedetomidine
group and continuous variable outcomes. Results are show in Table C4. One patient in the
No Dexmedetomidine group had a LOS of 32 days and was excluded as an outlier (shown
previously in Fig. 4). Inclusion in the Dexmedetomidine group was not significantly
associated with hospital LOS (Coefficient -0.1 days, 95%CI: [-0.9, 0.6], p = 0.71, Table
C4), post-operative change in creatinine (Coefficient -0.01 mg/dL, 95%CI: [-0.1, 0.1], p =
0.84), post-operative change in hemoglobin (Coefficient -0.2 g/dL, 95%CI: [-0.7, 0.2], p =
0.35), or creatinine at discharge (Coefficient -0.01 mg/dL, 95%CI: [-0.2, 0.2], p = 0.93).
Conversely, peripheral arterial disease was associated with an increase in discharge
creatinine (Coefficient 0.5 mg/dL, 95%CI: [0.3, 0.7], p = <0.0001).
Table C4 - Dexmedetomidine vs. No Dexmedetomidine
Linear Regression Analyses
Regression
Outcome

Variable

Hospital length of
stay (days)
(one outlier
excluded from the
No Dex group)

Dexmedetomidine (versus
No Dexmedetomidine)
Peripheral arterial disease
Procedure Year
Propofol Dose, mg/kg/hr

Change in
Creatinine, pre to
post-procedure
(mg/dL)

Dexmedetomidine
Peripheral arterial disease
Procedure Year
Propofol Dose, mg/kg/hr
Dexmedetomidine

Coefficient

95% CI

P Value

-0.145

-0.917, 0.626

0.71

0.195
-0.055
-0.276
-0.012
0.096
-0.037
0.009
-0.216

-0.661, 1.052
-0.551, 0.441
-0.717, 0.164

0.65
0.83
0.22

-0.134, 0.109
-0.039, 0.231
-0.115, 0.041
-0.061, 0.078

0.84
0.16
0.35
0.81

-0.675, 0.243

0.35
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Change in
Hemoglobin, pre
to post-procedure
(g/dL)

Creatinine at
discharge (mg/dL)

Peripheral arterial disease
Procedure Year
Propofol Dose, mg/kg/hr
Dexmedetomidine
Peripheral arterial disease
Procedure Year
Propofol Dose, mg/kg/hr

0.094
-0.147
0.060

-0.415, 0.604
-0.442, 0.149

0.72
0.33

-0.203, 0.322

0.65

-0.010
0.498
0.019
-0.013

-0.233, 0.214
0.250, 0.746
-0.125, 0.163
-0.141, 0.115

0.93
<0.0001 *
0.80
0.85

Table C5 shows results of logistic regression analysis. The Dexmedetomidine
group had no significant association with incidence of post-operative PPM (Odds Ratio
0.8, 95%CI: [0.3, 1.9], p = 0.51, Table C1) or with RBC transfusion (OR 0.5, 95%CI: [0.1,
1.6], p = 0.25). 38 patients had pre-existing PPMs and were excluded from the PPM
analysis (n=14, 16.3% and n=24, 12.9%, Table C1). Finally, cox proportional hazard
analysis found no association between the Dexmedetomidine group and mortality (Hazard
Ratio 1.0, 95%CI: [0.6, 1.9], p = 0.82, Table C6).
Table C5 - Dexmedetomidine vs. No Dexmedetomidine
Logistic Regression Analyses
Regression
Outcome

Variable

Post-operative PPM,
excluding preexisting PPM (n=
234)

RBC transfusion

Odds Ratio

95% CI

0.781

0.307, 1.911

0.59

1.080
0.991
0.899
0.511
1.638
1.690
0.476

0.372, 2.747
0.563, 1.797
0.525, 1.483
0.148, 1.557
0.430, 5.156
0.794, 3.979
0.196, 0.998

0.88
0.98
0.68
0.25
0.42
0.20
0.07

Dexmedetomidine (versus No
Dexmedetomidine)
Peripheral arterial disease
Procedure Year
Propofol Dose, mg/kg/hr
Dexmedetomidine
Peripheral arterial disease
Procedure Year
Propofol Dose, mg/kg/hr

P Value

Table C6 - Dexmedetomidine vs. No Dexmedetomidine
Cox Proportional Hazard Model Outcomes
Regression
Outcome

Mortality

Variable
Dexmedetomidine
Peripheral arterial disease
Procedure Year
Propofol Dose, mg/kg/hr

Odds Ratio

95% CI

1.071
1.146
1.000
0.790

0.603, 1.903
0.607, 2.163
0.999, 1.000
0.550, 1.133

P Value
0.82
0.68
0.57
0.20
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DISCUSSION
TAVR has rapidly become a common treatment for severe, symptomatic AS, and
more TAVR procedures are being completed under CS instead of GA than ever before.24
Despite growing popularity of CS or Monitored Anesthesia Care (MAC; CS administered
by an anesthesiologist) in TAVR, there has been limited investigation into the optimal
MAC medications for TAVR patients. The current study retrospectively analyzed
outcomes after TAVR for three different medication group comparisons: Propofol versus
No Propofol (Analysis A), Propofol plus midazolam versus Propofol only (Analysis B),
and Dexmedetomidine versus No Dexmedetomidine (Analysis C). The study found that for
each analysis, the medication group had no significant association with total hospital LOS,
mortality, and need for PPM. Additionally, there were no significant differences between
the groups in each analysis for secondary outcomes of interest, including: in-hospital death,
discharge location, change in creatinine from pre- to post-procedure, change in hemoglobin
from pre- to post-procedure, creatinine at discharge, and need for post-operative RBC
transfusion.
The lack of significant association between MAC medication and outcomes is
consistent with previous findings from Khalil et al.,40 Mayr et al.,41 Chen et al.,42 and
Kronfli et al.43 Each of these prior studies found no difference in post-operative outcomes
between the comparator medication groups (propofol-opioid vs. dexmedetomidine;
propofol vs. propofol plus dexmedetomidine; or propofol only vs. dexmedetomidine only).
However, the lack of difference in these and the current study does not rule out the
possibility that a certain MAC regimen is truly associated with better or worse outcomes
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after TAVR. It is possible that a difference does exist but has not been detected due to small
sample sizes and low frequency of events, resulting in underpowered analyses.
Results from the current study do indicate that it is possible that propofol plus
midazolam may be suboptimal for TAVR compared to propofol only. In Analysis B, the
Propofol plus midazolam group had greater incidence of hypotension as a causative factor
of prolonged LOS, although the increase in incidence was not significant in unadjusted
analysis (55.5% versus 17.4%, p = 0.075, Table B3) or in adjusted analysis (Odds Ratio
5.79, 95%CI: [0.63, 81.6], p = 0.14, Table B5). This is of interest despite lack of
significance, because the Propofol plus midazolam group had a larger percentage of
patients affected by hypotension leading to prolonged LOS despite having a younger and
less ill cohort than the Propofol only group. This regimen notably combines two
medications known to synergize and to cause cardiovascular depression, and propofol plus
midazolam has been associated with worse outcomes in other procedures; in a randomized
study comparing outcomes for endoscopy patients treated with propofol only (n=120)
versus propofol plus midazolam (n=119), propofol plus midazolam resulted in significantly
longer recovery time and a significantly lower recovery quality (based on patient scoring),
despite achieving similar efficacy of intra-operative sedation.48 Therefore, this study
indicates further exploration of the effects of propofol plus midazolam versus propofol only
in MAC for TAVR may be warranted. It is possible that with a greater sample size, the
association between Propofol plus midazolam and post-operative hypotension could
become significant.
Some of the baseline patient characteristics did vary significantly between the
groups in each analysis. The variation was very likely due to the lack of randomization and

40

retrospective nature of this study. First, patients in the Propofol group had fewer preexisting permanent pacemakers (11% versus 23%, p = 0.02, Table A1). Anesthetic agents
are not expected to negatively affect the function of PPMs,67 but propofol has potential to
be pro-arrhythmic by blocking or drastically slow conduction. It is possible that providers
may have avoided propofol in patients with pacemakers due to this potentially proarrhythmic effect, but the literature linking propofol to increased risk of arrhythmias is
mixed and lacking.52 Patients in the Propofol group were also less likely to have had left
main coronary disease (8% versus 17%, p=0.054, Table A1). This association was likely
because providers were wary of the effects of propofol on cardiac function and
hemodynamic in patients with coronary artery disease (CAD). Propofol has been shown to
reduce systolic and diastolic blood pressure, myocardial blood flow, and myocardial
oxygen consumption in CAD patients.68-70
Next, patients in the Propofol plus midazolam group were younger (78.8 year ± 8.3
versus 85.9 years ± 6.0, p <0.0001, Table B1) and had lower STS risk score (5.3 ± 3.7
versus 6.4 ± 5.3, p = 0.04, Table B1). It is possible that the association of the Propofol plus
midazolam group with age and STS Risk Score is due to providers preferring to use a
combination of synergistic medications in younger, potentially less sedation-sensitive
patients. It is recognized that co-administration of propofol and midazolam results in
increased sedative and cardio-respiratory depression effects of both medications,33,34 with
the combination resulting in deeper sedation and more frequent deep sedation than propofol
alone.22,44 It is also recognized that elderly patients are more sensitive to both propofol71,72
and midazolam,73 and it is sensible that providers would avoid this exposure.
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Lastly, more patients treated in the Dexmedetomidine group had prior peripheral
arterial disease (PAD, 26.7% versus 13.4%, p = 0.01, Table C1). This may be due to
institutional or provider preference, since choice of MAC medications used in patients with
PAD does not have strict guidelines.74 Kronfli et al. also had a dexmedetomidine group
with significantly more patients with prior PAD than the propofol group (78.6% versus
72.7%, p = 0.024), but this difference is not explained.43 There may be some advantage to
use of dexmedetomidine over midazolam for patients with PAD; in a randomized study
treated PAD patients with either dexmedetomidine plus remifentanil or midazolam plus
remifentanil, patients treated with dexmedetomidine had significantly lower post-operative
pain scores and higher satisfaction.75
There were differences in the doses of other MAC medications received in each
group. First, patients in the Propofol group (Analysis A) received less dexmedetomidine
(20.7% versus 65.6%, p <0.0001, Table A2) and less remifentanil (13.3% versus 40.6%, p
<0.0001, Table A2) than patients in the No Propofol group. This is expected, because the
propofol group will have received propofol, reducing the need for other medications to
achieve adequate sedation. Similarly, patients in the Propofol plus midazolam group
(Analysis B) received less remifentanil (8.6% versus 22.3%, p = 0.02, Table B2) compared
to patients in the Propofol only group. However, the Propofol plus midazolam group
received more fentanyl than the Propofol only group (0.52 ± 0.2 mcg/kg/hr versus 0.35 ±
0.2 mcg/kg/hr, p = 0.0002, Table B2). This is possibly because fewer Propofol plus
midazolam patients received remifentanil overall (8.6% versus 22.3%), so there were more
patients in the group who received fentanyl as the only opioid. It is possible that patient
who otherwise would have also received remifentanil received a higher dose of fentanyl
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instead, raising the group mean dose. Lastly, fewer patients in the Dexmedetomidine group
(Analysis C) were treated with propofol (50% versus 88.2%, p < 0.0001, Table C2),
indicating that patients given dexmedetomidine may need and receive less propofol to
attain adequate sedation.
Even though the studied CS medication groups were ultimately not associated with
outcomes of interest, other variables that were included in the regression analyses were
significantly associated with outcomes. In Analysis B, STS Risk score was associated with
a 0.13 day increased in LOS (Coefficient 0.13 days, 95%CI: [0.05, 0.2], p = 0.002, Table
B4) and an increased hazard of post-operative mortality (Hazard Ratio 1.12, 95%CI: [1.04,
1.21], p = 0.003, Table B6). Both of these associations are expected, since STS Risk Score
is intentionally designed to predict outcomes including length of hospital stay and mortality
after valve replacement.76 STS Risk score was also independently associated with an
increase in post-operative blood transfusion (Odds Ratio 1.21, 95%CI: [1.05, 1.40], p =
0.008, Table B5). Need for post-TAVR transfusion is commonly due to intraprocedural
vascular damage and complications leading to blood loss during and after the procedure.77
It is possible that increase in STS Risk score leads to increased transfusion, because patients
with higher scores are sicker and may be more susceptible to vascular injury and less
resilient due to comorbidities and frailty.
In Analysis B, BMI was independently associated with an increase in creatinine
before versus after the TAVR (Coefficient 0.015 mg/dL, 95%CI: [0.003, 0.028], p = 0.016,
Table B4) and with an increase in creatinine at discharge (Coefficient 0.028 mg/dL,
95%CI: [0.008, 0.048], p = 0.007, Table B4). This can be explained by previous evidence
showing that increased patient BMI is associated with increased risk of acute kidney injury
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after surgery and a greater post-procedural increase in creatinine.78-80 Additionally in
Analysis B, atrial fibrillation was independently associated with mortality (Hazard Ratio
2.3, 95%CI: [1.08, 4.8], p = 0.03, Table B6). This corroborates findings that patients with
atrial fibrillation suffer from an increased risk of all-cause mortality compared to the
general population.81,82 Lastly, in Analysis C, PAD was associated with an increase in
discharge creatinine (Coefficient 0.5 mg/dL, 95%CI: [0.25, 0.75], p < 0.0001, Table C4).
The increase in creatinine is likely secondary to perioperative renal hypoperfusion due to
vascular disease. Indeed, PAD is a risk factor for acute kidney injury following surgery.83,84
This study has several key limitations. First, this is a retrospective study, so biases
in patient selection and distribution to MAC groups were not controlled for. Indeed, there
were noted differences in baseline characteristics. Multivariate regression should have
helped account for these differences, although it is still possible that unknown variables
may have confounded the effects of recorded variables. Additionally, study data is limited
by what was recorded accurately in the chart. Next, this analysis did not take into account
patient ASA score (I-VI), which may have contributed to provider decision-making in
choosing a MAC regimen. Next, the sample size for the current study was still relatively
small, and effects of medication groups may be hidden by underpowered analyses. The
sample sizes were limited by heterogeneity of medication combinations used in the
surveyed sample. Lastly, Analysis A and Analysis C were comparisons of aggregate
groups, meaning patients in the Propofol group for Analysis A could also have been treated
with dexmedetomidine or midazolam. While the analysis accounted for frequency and dose
of other medications to control for this additional variable, this adjustment may not have
fully accounted for potential drug synergies.
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In this single institution patient population, MAC medication group was not
significantly associated with outcomes of interest, including total hospital LOS, mortality,
and need for post-operative PPM. These findings suggest that within MAC, specific
medication choice may not significantly affect clinically impactful outcomes after TAVR.
However, it is still possible that a difference exists and requires a larger cohort to be
detected. Further investigation is warranted, because even small improvements in
outcomes related to MAC medications could be magnified and generate tangible gains in
quality and cost of TAVR patient care. In particular, testing of propofol plus midazolam
versus propofol only or midazolam only is warranted, because propofol plus midazolam
may prolong recovery and resulting hospital LOS due to synergistic cardiovascular
depressant effects.
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